Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021390 (inflammatory bowel disease)
 23,302 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We describe a patient who developed cutaneous gangrene secondary to microvascular thrombosis, an uncommon complication of inflammatory bowel disease with potentially serious manifestations.
Clin Exp Dermatol 1989 Sep
PMID:Cutaneous gangrene secondary to focal thrombosis--an important cutaneous manifestation of ulcerative colitis. 261 46

Forty seven patients with suspected malignant disease (mainly colorectal cancer) were studied with 111In labelled F(ab')2 fragments of an anti-CEA monoclonal antibody (BW 431/31). The kinetic data revealed a long whole body retention of the label (62% after 4 days) and a rapid blood clearance (77% within 24 h, 89% within 48 h) leading to an early positive tumour contrast 24 h p.i. and optimal scintigrams 48 h p.i. Diagnostic results were promising in local recurrences of colorectal cancer (8/10 positive = 80%) though false positive findings in patients with inflammatory bowel disease occurred probably due to cross-reaction with a human granulocyte antigen. Liver metastases and tumours neighbouring liver and spleen were often missed (10/27 = 37%) because of high nonspecific uptake in these organs. Thus BW 431/31 proved to be a suitable compound for radioimmunodetection, however, further improvements to optimize tumour affinity and specificity of the antibody are mandatory.
Nucl Med Commun 1989 Sep
PMID:Radioimmunoscintigraphy with 111In labelled monoclonal antibody fragments (F(ab')2 BW 431/31) against CEA: radiolabelling, antibody kinetics and distribution, findings in tumour and non-tumour patients. 261 3

Serial assessments of respiratory function were made in 44 patients with inflammatory bowel disease. Pulmonary function tests were performed at the initial assessment and after three months to see if abnormality was associated with alteration in disease activity, drug therapy or with evidence of immunological disturbance. Fourteen patients (32%) had some abnormality of respiratory function when first investigated. Seven (16%) had a reduced gas transfer factor but these abnormalities were not related to disease activity, drug therapy or any immunological variable. Elevation of both functional residual capacity and residual volume was found in nine (20%) patients at the initial assessment. These abnormalities appeared to be associated with active inflammatory bowel disease and in four of these patients lung volumes returned to normal at 3 months when the bowel disease was in remission.
Respir Med 1989 Sep
PMID:Respiratory impairment in inflammatory bowel disease: does it vary with disease activity? 261 23

Pyoderma gangrenosum (PG) is an uncommon ulcerative cutaneous condition with distinctive clinical characteristics and a frequent association with systemic diseases. Most frequently among the associated disease list are: inflammatory bowel disease, arthritis, and a variety of hematologic disorders. There is no specific treatment of PG; however, the effective treatment of an accompanying systemic disease, local therapy, and/or the use of topical or systemic agents known to be useful in neutrophil disorders, have been beneficial in most patients.
Med Clin North Am 1989 Sep
PMID:Pyoderma gangrenosum and related disorders. 267 44

Since the institution of successful parenteral nutrition, much has been learned about malnutrition and the effects and complications of nutritional therapy. A variety of patient groups suffer from malnutrition, and clinicians accept the fact that an extremely high incidence of hospitalized medical and surgical patients are malnourished. Perhaps the group we most frequently see suffering from malnutrition are patients with inflammatory bowel disease (IBD). This is especially true in Crohn's disease, in which a variety of nutritional disturbances have been described.
Gastroenterol Clin North Am 1989 Sep
PMID:Trace element deficiencies in inflammatory bowel disease. 268 Sep 67

Epidemiological data indicate that exogenous noxes are important in the etiology of nonspecific inflammatory bowel disease. In several studies the influence of nutritional factors in the pathogenesis of Crohn's disease was investigated. The conflicting results, the inappropriate methods of investigation, the limited number of patients, and differences between patients and controls in many of these studies require a careful interpretation. Evidence for an etiological significance of nutrition in the development of Crohn's disease is still missing. Therefore, a specific diet for these patients does not exist. The physician should recommend a balanced diet which considers the needs in energy supply, corrects preexisting deficiencies, and is adapted to subjective intolerances and to disease related complications such as malabsorption or partial intestinal obstruction.
Z Gastroenterol 1989 Sep
PMID:[Nutrition and Crohn disease--an etiologic factor?]. 268 38

The preparation Mutaflor contains a defined strain of physiological E. coli bacteria. One hundred and sixty-seven physicians documented the treatment of 1,074 patients suffering from functional or chronic inflammatory bowel disease. For all indications the tolerance of Mutaflor was judged to be good to very good in over 90% of the cases. Adverse reactions which needed treatment or led to termination of the therapy, were reported in 1.5% of the cases. Initially occurring side effects, which did not need treatment and disappeared spontaneously, were observed in 2.8% of the cases. Interactions with additional or concomitant drugs did not occur. As a parameter for the evaluation of efficacy, the subjective assessment of the results by physicians and patients was used. In 84% of the patients with functional intestinal disorders and 78% of the patients with chronic inflammatory bowel disease results of treatment were judged to be good to very good.
Fortschr Med 1989 Sep 30
PMID:[The treatment of intestinal diseases with Mutaflor. A multicenter retrospective study]. 269 88

The assessment of health-related quality of life may be an adjunct to understanding the chronic illness experience and its effects on health outcomes. In this study, we evaluated health-related quality of life of 150 patients with inflammatory bowel disease (63 ulcerative colitis, 87 Crohn's disease). We used a standardized measure, the Sickness Impact Profile, and a questionnaire we developed that elicits and prioritizes the disease-related worries and concerns of patients with IBD. Our preliminary data indicate that: (1) IBD patients experience moderate functional impairment more in the social and psychological than in the physical dimensions; (2) Crohn's disease patients report psychosocial dysfunction to a greater degree than ulcerative colitis patients; (3) IBD patients report greatest concerns about having surgery, degree of energy, and body image issues such as having an ostomy bag; and (4) functional status and patient concerns correlate better with other measures of health status and previous health care utilization than the physician's rating of disease activity. We believe that questionnaires measuring health-related quality of life (HRQOL) can be used in research and patient care to extend the clinical assessment of patients with IBD. Further work is needed to determine the role of HRQOL relative to disease activity and other physician-based assessments in predicting health outcomes.
Dig Dis Sci 1989 Sep
PMID:Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. 276 5

The effect of cyclosporin A in acute and chronically active inflammatory bowel disease was tested in 11 patients with Crohn's disease and two with ulcerative colitis who had exhibited a poor response to at least eight weeks of conventional therapy. Trough levels of the drug in the therapeutic range were obtained in 12 of 13 patients. Cyclosporin A, which was usually added to the continued previous medication, including corticosteroids (11 of 13) or metronidazol (1 of 13), prompted an apparent clinical improvement in all but one patient. In six of the nine Crohn's disease patients with an initial Best index of greater than 150, a definite fall by at least 100 points was observed after 2-10 weeks of treatment, but the van Hees index declined only in two patients. All four patients with chronic perineal fistulation experienced symptomatic relief. Both patients with ulcerative colitis had a clinical remission. Erythrocyte sedimentation rate or serum albumin improved in eight of 13 patients. However, two of the nine responders with Crohn's disease relapsed during cyclosporin A therapy and three immediately after the medication was discontinued. Common side effects included hypertrichosis, tremor, and hyperesthesia; hypertension and epigastric pain each occurred only in one patient.
Dig Dis Sci 1989 Sep
PMID:Cyclosporin A treatment in inflammatory bowel disease. 276 6

Ileocecal mass is occasionally encountered unexpectedly by surgeons operating for presumed appendicitis. A five-year retrospective study was performed to review the management of this problem. Thirteen patients were identified who had had right hemicolectomy performed for unexpected mass in which neoplasm, diverticular disease, or inflammatory bowel disease could not be differentiated from severe appendicitis at laparotomy. Seven patients (group 1) had a final pathologic diagnosis of appendiceal phlegmon. The other patients (group 2) had Crohn's disease, typhlitis, or neoplasm. Right hemicolectomy was performed with a morbidity of 7% and mortality of 7% in all patients. This procedure is acceptable for unexpected cecal mass.
Arch Surg 1989 Sep
PMID:Evaluation of right hemicolectomy for unexpected cecal mass. 277 5


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>